Harold J. Manley
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Harold J. Manley has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Carrie A. Cannella
1 shared publicationCharles L Welch
Charles L Welch PhD, Director of Laboratory, Research Medical Center, Kansas City
1 shared publicationGeorge R Bailie
George R Bailie PharmD PhD, Professor of Pharmacy Practice, Albany College of Pharmacy
1 shared publicationGeorge R. Bailie
1 shared publicationKatie E. Pallotta
Albany College of Pharmacy, Albany, New York 12208, USA
1 shared publicationM.L. McClaran
Dialysis Clinic, Inc, Kansas City, MO - USA
1 shared publication
Latest Publications
- 21 August 2007
- Published by Wiley in Seminars in Dialysis
- Vol. 21 (1) , 63-70
Vancomycin Use in Patients Requiring Hemodialysis: A Literature Review
Vancomycin, a glycopeptide antibiotic, has remained a popular antimicrobial agent throughout the past five decades, and is often included in empiric antibiotic regimens. With gram‐positive coverage, it has found a niche in the treatment of methicillin‐resistant Staphylococcus aureus. Although vancomycin has been in existence for many years, questions remain regarding its use. New technologies and practice pattern changes have occurred over the years that altered vancomycin dosing in hemodialysis (HD) patients. Examples of these changes include increased resistance of many organisms, development of high flux HD filters, and reprocessing practices. This review provides a summary of the several concerns that exist in the dosing of vancomycin in HD patients today, and provides a summary table of intradialytic dosing regimens.
- 21 August 2007
- Published by Wiley in Seminars in Dialysis
- Vol. 21 (1) , 63-70
Vancomycin Use in Patients Requiring Hemodialysis: A Literature Review
Vancomycin, a glycopeptide antibiotic, has remained a popular antimicrobial agent throughout the past five decades, and is often included in empiric antibiotic regimens. With gram‐positive coverage, it has found a niche in the treatment of methicillin‐resistant Staphylococcus aureus. Although vancomycin has been in existence for many years, questions remain regarding its use. New technologies and practice pattern changes have occurred over the years that altered vancomycin dosing in hemodialysis (HD) patients. Examples of these changes include increased resistance of many organisms, development of high flux HD filters, and reprocessing practices. This review provides a summary of the several concerns that exist in the dosing of vancomycin in HD patients today, and provides a summary table of intradialytic dosing regimens.
- 1 November 2006
- Published by SAGE Publications in The International Journal of Artificial Organs
- Vol. 29 (11) , 1062-1066
Determination of VIT 45 (IND#63,243 - American Regent) Removal by Closed Loop in Vitro Hemodialysis System
Background: Intravenous iron is typically administered during the hemodialysis (HD) procedure. The extent of VIT 45, a novel intravenous iron formulation, removal by high-flux (HF) or high-efficiency (HE) dialysis membranes at various ultrafiltration rates (UFR) is unknown. Methods: An in vitro HD system was constructed to determine the dialyzabiltiy of iron from a normal saline compartment (NSC) containing 1000 mg iron of VIT 45. The in vitro system utilized a 6-L closed-loop SBS system that was subject to 4 different HD conditions conducted over 4 hours: HE membrane + 0 ml/h UFR; HE membrane + 500 ml/h UFR; HF membrane + 0 ml/h UFR; HF membrane + 500 ml/h UFR. Blood flow and dialysate flow rates were 500 ml/min and 800 ml/min, respectively. The dialysate compartment was a 6-L closed-loop system. A volumetric HD machine controlled all blood, dialysate, and ultrafiltration rates. NSC and dialysate compartment samples were taken at various time points and iron elimination rate (khd) and HD clearance (Clhd) was determined. Iron removal from the NSC > 15% was considered clinically significant. Results: The percent removal of iron from the NSC was < 0.5% at all time points in the study. Dialysate recovery of iron was negligible: 1.7–5.1 mg. VIT 45 removal elimination rates from NSC were less than -0.001 h −1 (range -0.0002 ± 0.0001 to -0.0001 ± 0.0002 h −1) for all study conditions. Dialyzer type or UFR did not effect iron removal. Conclusion: HF or HE dialysis membranes do not remove clinically significant amounts of VIT 45 over a 4-hour in vitro HD session. This effect remained constant even controlling for UFR up to 500 ml/hour. VIT 45 is not dialyzed by HE or HF dialysis membranes irrespective of UFR. (Int J Artif Organs 2006; 29: 1062–6)
- 1 November 2006
- Published by SAGE Publications in The International Journal of Artificial Organs
- Vol. 29 (11) , 1062-1066
Determination of VIT 45 (IND#63,243 - American Regent) Removal by Closed Loop in Vitro Hemodialysis System
Background: Intravenous iron is typically administered during the hemodialysis (HD) procedure. The extent of VIT 45, a novel intravenous iron formulation, removal by high-flux (HF) or high-efficiency (HE) dialysis membranes at various ultrafiltration rates (UFR) is unknown. Methods: An in vitro HD system was constructed to determine the dialyzabiltiy of iron from a normal saline compartment (NSC) containing 1000 mg iron of VIT 45. The in vitro system utilized a 6-L closed-loop SBS system that was subject to 4 different HD conditions conducted over 4 hours: HE membrane + 0 ml/h UFR; HE membrane + 500 ml/h UFR; HF membrane + 0 ml/h UFR; HF membrane + 500 ml/h UFR. Blood flow and dialysate flow rates were 500 ml/min and 800 ml/min, respectively. The dialysate compartment was a 6-L closed-loop system. A volumetric HD machine controlled all blood, dialysate, and ultrafiltration rates. NSC and dialysate compartment samples were taken at various time points and iron elimination rate (khd) and HD clearance (Clhd) was determined. Iron removal from the NSC > 15% was considered clinically significant. Results: The percent removal of iron from the NSC was < 0.5% at all time points in the study. Dialysate recovery of iron was negligible: 1.7–5.1 mg. VIT 45 removal elimination rates from NSC were less than -0.001 h −1 (range -0.0002 ± 0.0001 to -0.0001 ± 0.0002 h −1) for all study conditions. Dialyzer type or UFR did not effect iron removal. Conclusion: HF or HE dialysis membranes do not remove clinically significant amounts of VIT 45 over a 4-hour in vitro HD session. This effect remained constant even controlling for UFR up to 500 ml/hour. VIT 45 is not dialyzed by HE or HF dialysis membranes irrespective of UFR. (Int J Artif Organs 2006; 29: 1062–6)
- 1 October 2005
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 46 (4) , 669-680
Medication-Related Problems in Ambulatory Hemodialysis Patients: A Pooled Analysis
- 1 October 2005
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 46 (4) , 669-680
Medication-Related Problems in Ambulatory Hemodialysis Patients: A Pooled Analysis
- 1 December 2004
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 38 (12) , 2035-2040
Intraperitoneal Cefazolin and Ceftazidime Effects on Human Peritoneal Mesothelial Cell Release of Cancer Antigen–125
BACKGROUND: Intraperitoneal (IP) cefazolin and ceftazidime are recommended as empiric treatment for peritoneal dialysis (PD)–associated peritonitis. Human peritoneal mesothelial cells (HPMCs) may be affected by high IP cefazolin and ceftazidime concentrations. Peritoneal dialysate cancer antigen–125 (CA-125) appearance rate can be used to measure HPMC damage. OBJECTIVE: To determine whether IP cefazolin and ceftazidime increase peritoneal CA-125 appearance rate. METHODS: The study consisted of 2 phases. In phase I, no antibiotic was administered, and in phase II, patients received IP cefazolin and ceftazidime (15 mg/kg rounded to nearest 100 mg). Phase II occurred immediately after phase I. Each phase used a 4-hour dwell time with 2 L of dextrose 2.5% dialysate. Dialysate samples were collected at 0, 0.5, 1, 2, and 4 hours during each phase. Samples were assayed for CA-125, and CA-125 appearance rate was calculated. RESULTS: Thirteen patients were recruited (7 men; aged 44.0 ± 16.0 y). The mean ± SD (range) CA-125 dialysate concentration after phases I and II were 6.6 ± 3.7 U/mL (2.3–15.0) and 6.4 ± 3.8 U/mL (1.6–13.8), respectively (p = 0.46). The CA-125 appearance rate after phases I and II were 51.9 ± 31.3 U/min/1.73 m 2 (13.8–113.0) and 50.5 ± 32.9 U/min/1.73 m 2 (11.0–104.0), respectively (p = 0.57). The slopes of the regression lines of CA-125 appearance rate were not significantly different between phases I and II. CONCLUSIONS: These findings demonstrate that concurrently administered IP cefazolin and ceftazidime have no effect on HPMC release of CA-125 in non-infected PD patients.
- 1 December 2004
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 38 (12) , 2035-2040
Intraperitoneal Cefazolin and Ceftazidime Effects on Human Peritoneal Mesothelial Cell Release of Cancer Antigen–125
BACKGROUND: Intraperitoneal (IP) cefazolin and ceftazidime are recommended as empiric treatment for peritoneal dialysis (PD)–associated peritonitis. Human peritoneal mesothelial cells (HPMCs) may be affected by high IP cefazolin and ceftazidime concentrations. Peritoneal dialysate cancer antigen–125 (CA-125) appearance rate can be used to measure HPMC damage. OBJECTIVE: To determine whether IP cefazolin and ceftazidime increase peritoneal CA-125 appearance rate. METHODS: The study consisted of 2 phases. In phase I, no antibiotic was administered, and in phase II, patients received IP cefazolin and ceftazidime (15 mg/kg rounded to nearest 100 mg). Phase II occurred immediately after phase I. Each phase used a 4-hour dwell time with 2 L of dextrose 2.5% dialysate. Dialysate samples were collected at 0, 0.5, 1, 2, and 4 hours during each phase. Samples were assayed for CA-125, and CA-125 appearance rate was calculated. RESULTS: Thirteen patients were recruited (7 men; aged 44.0 ± 16.0 y). The mean ± SD (range) CA-125 dialysate concentration after phases I and II were 6.6 ± 3.7 U/mL (2.3–15.0) and 6.4 ± 3.8 U/mL (1.6–13.8), respectively (p = 0.46). The CA-125 appearance rate after phases I and II were 51.9 ± 31.3 U/min/1.73 m 2 (13.8–113.0) and 50.5 ± 32.9 U/min/1.73 m 2 (11.0–104.0), respectively (p = 0.57). The slopes of the regression lines of CA-125 appearance rate were not significantly different between phases I and II. CONCLUSIONS: These findings demonstrate that concurrently administered IP cefazolin and ceftazidime have no effect on HPMC release of CA-125 in non-infected PD patients.